|
KMID : 1146920230530050643
|
|
Journal of Pharmaceutical Investigation
2023 Volume.53 No. 5 p.643 ~ p.665
|
|
|
Current application of dexamethasone-incorporated drug delivery systems for enhancing bone formation
|
|
Thi Phuong Mai
Park Jun-Beom
Huu Duc Nguyen
Min Kyoung-Ah
Moon Cheol
|
|
|
Abstract
|
|
|
Background : Dexamethasone (DEX) is a well-known anti-inflammatory and immunosuppressive drug applied broadly as an osteoinductive agent in bone remodeling. However, the efficacy of DEX is strongly dependent on the dosage and duration of application. Therefore, the optimization of DEX release with the appropriate concentration is crucial for bone tissue engineering.
Area covered : This review discusses the incorporation of DEX into drug delivery systems such as nanoparticles, microparticles, and scaffolds, and their effects on bone fracture healing by controlling the long-term release of the drug and preventing systemic side effects. The mechanism of DEX in bone fracture repair and the potential outcomes of DEX-contained approaches for bone regeneration and the osteogenic process are also summarized.
Expert opinion : DEX-incorporated drug delivery technologies, such as micro- and nanoparticles and scaffolds, hold great promise for the treatment of bone defects. These systems offer several advantages, including enhanced DEX stability, controlled release with appropriate concentration levels, targeted delivery to the treatment site, inhibition of cytotoxicity, and prevention of systemic side effects of DEX. However, further rigorous research is necessary to optimize DEX-incorporated drug delivery systems and conduct detailed assessments of their in vitro and in vivo osteogenesis and bone formation, as well as determine the optimal application processes.
|
|
|
KEYWORD
|
|
|
Dexamethasone, Bone regeneration, Osteogenesis, Drug delivery systems
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|